Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.
Company Profile
Latest Presentation
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical Preparations (2834)
Contact Information
Investor Relations
Adanna G. Alexander, PhD
T: (646) 942-5603
Adanna@RussoPR.com
Madison Damour
madison@anebulo.com
Company Contact
Anebulo Pharmaceuticals, Inc.
1415 Ranch Road 620 South
Austin, TX 78734
T: 512-598-0931
ir@anebulo.com